Signaturefd LLC Buys 1,151 Shares of Xencor, Inc. (NASDAQ:XNCR)

Signaturefd LLC lifted its holdings in shares of Xencor, Inc. (NASDAQ:XNCR) by 367.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,464 shares of the biopharmaceutical company’s stock after purchasing an additional 1,151 shares during the period. Signaturefd LLC’s holdings in Xencor were worth $31,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. BluePath Capital Management LLC bought a new stake in shares of Xencor during the 3rd quarter worth $31,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Xencor by 95.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,548 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 756 shares during the period. Allworth Financial LP raised its stake in shares of Xencor by 29,487.5% during the 4th quarter. Allworth Financial LP now owns 2,367 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 2,359 shares during the period. Exchange Traded Concepts LLC raised its stake in shares of Xencor by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 6,776 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 1,718 shares during the period. Finally, Hsbc Holdings PLC bought a new stake in shares of Xencor during the 3rd quarter worth $213,000.

Insider Buying and Selling at Xencor

In other news, Director Kurt A. Gustafson sold 14,000 shares of the business’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $23.18, for a total transaction of $324,520.00. Following the completion of the transaction, the director now owns 6,007 shares of the company’s stock, valued at $139,242.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Kurt A. Gustafson sold 14,000 shares of the firm’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $23.18, for a total transaction of $324,520.00. Following the sale, the director now owns 6,007 shares in the company, valued at approximately $139,242.26. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP John R. Desjarlais sold 1,280 shares of Xencor stock in a transaction on Monday, March 11th. The stock was sold at an average price of $23.50, for a total transaction of $30,080.00. Following the sale, the vice president now directly owns 186,433 shares of the company’s stock, valued at $4,381,175.50. The disclosure for this sale can be found here. Insiders have sold a total of 101,351 shares of company stock valued at $2,152,417 in the last 90 days. Corporate insiders own 4.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on XNCR. Royal Bank of Canada reiterated an “outperform” rating and set a $32.00 target price on shares of Xencor in a research note on Wednesday, February 28th. BTIG Research lowered their price objective on Xencor from $56.00 to $38.00 and set a “buy” rating on the stock in a research note on Tuesday, April 16th. Mizuho lowered their price objective on Xencor from $59.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, January 22nd. StockNews.com upgraded Xencor from a “sell” rating to a “hold” rating in a research note on Saturday, March 9th. Finally, Wedbush lowered their price objective on Xencor from $36.00 to $34.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 28th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Xencor currently has an average rating of “Moderate Buy” and a consensus target price of $36.00.

Xencor Stock Up 2.0 %

Shares of NASDAQ:XNCR opened at $24.11 on Friday. The firm has a fifty day moving average price of $21.88 and a two-hundred day moving average price of $20.47. The company has a market cap of $1.49 billion, a price-to-earnings ratio of -11.48 and a beta of 0.77. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.36 and a quick ratio of 7.36. Xencor, Inc. has a one year low of $16.49 and a one year high of $28.96.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.67). Xencor had a negative return on equity of 18.67% and a negative net margin of 74.90%. The business had revenue of $44.70 million during the quarter, compared to analysts’ expectations of $77.63 million. During the same quarter last year, the business posted ($0.20) EPS. The company’s quarterly revenue was up 106.9% on a year-over-year basis. Analysts anticipate that Xencor, Inc. will post -3.25 EPS for the current fiscal year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.